Genome Editing

Inequality and global instability | 7/19/2020

Yehezkel Dror, Israel’s top public policy expert: He lists 23 challenges that the new era poses, seven of which he says require immediate action: “atomic weapons; climate change; cybersphere; energy; genome editing and synthetic biology; high-energy experiments; and extreme global inequality” – the last of which Dror sees primarily as a threat to stability, not as a moral problem. Aluf Benn Jul. 17, 2020, ‘There’s no alternative to Netanyahu; our …

LogicBio Therapeutics (NASDAQ:LOGC) Downgraded by Zacks Investment Research to “Hold” | 7/19/2020

… Investment Research lowered shares of LogicBio Therapeutics (NASDAQ:LOGC) from a buy rating to a hold rating in a report published on Wednesday morning, Zacks.com reports. According to Zacks, “LogicBio Therapeutics Inc. is a genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The company’s technology platform consists of GeneRide(TM). LogicBio Therapeutics Inc. is based in Cambridge, Massachusetts. “ Get …

Follow Genome Editing:    

Reviewing Precision BioSciences (NASDAQ:DTIL) and Idera Pharmaceuticals (NASDAQ:IDRA) | 7/18/2020

… Pharmaceuticals is more favorable than Precision BioSciences. Summary Idera Pharmaceuticals beats Precision BioSciences on 8 of the 14 factors compared between the two stocks. Precision BioSciences Company Profile Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment …

Head-To-Head Review: Precision BioSciences (NASDAQ:DTIL) versus Regenxbio (NASDAQ:RGNX) | 7/18/2020

Precision BioSciences beats Regenxbio on 7 of the 13 factors compared between the two stocks. About Precision BioSciences Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer …

Precision BioSciences (NASDAQ:DTIL) Downgraded by Zacks Investment Research | 7/18/2020

… Investment Research lowered shares of Precision BioSciences (NASDAQ:DTIL) from a hold rating to a sell rating in a report released on Wednesday, Zacks.com reports. According to Zacks, “Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina. “ Get …

Tiny Cas Protein, Huge Gene Editing Potential ‌ Thanks, Megaphage! | 7/17/2020

… is shown in purple. [UC Berkeley image by Basem Al-Shayeb and Patrick Pausch] The article’s authors, scientists based at the University of California (UC), Berkeley, noted that CasΦ should be useful for both genome editing and DNA detection. Also, they emphasized that the hypercompact CasΦ offers advantages for cellular delivery that expand the genome editing toolbox. Smaller and more compact Cas proteins are easier to ferry into cells to …

Newly identified enzyme provides a new tool in CRISPR genome editing toolbox | 7/17/2020

… yet exclusively harbor the genetically unique and unusually tiny CasΦ enzyme. Here, Pausch, Doudna and colleagues describe the functionality of the phage-derived CRISPR-CasΦ system and demonstrate its potential for expanding the CRISPR genome editing toolbox. Despite being nearly half the size of Cas9 and Cas12 systems commonly used for genome editing, Pausch et al. show that the biochemically unique CasΦ is fully functional and capable of both producing …

Doudna’s team identifies new ‘hypercompact’ CRISPR enzyme | FierceBiotech | 7/17/2020

… CasX , use one or two active sites for DNA cutting and rely on a separate active site or additional factors for crRNA processing, according to the researchers. The team showed CRISPR-CasΦ can perform genome editing in both human and plant cells. In one case, a variant of CasΦ was able to edit up to 33% of human cells, which is comparable to levels initially reported for the three above …

Megaphages harbor mini-Cas proteins ideal for gene editing | Phys Org | 7/17/2020

… viruses, called bacteriophages, and are the most compact working Cas variants yet discovered—half the size of today’s workhorse, Cas9. Smaller and more compact Cas proteins are easier to ferry into cells to do genome editing , since they can be packed into small delivery vehicles, including one of the most popular: a deactivated virus called adeno-associated virus (AAV). Hypercompact Cas proteins also leave space inside AAV for additional cargo …

Precision BioSciences (NASDAQ:DTIL) Lowered to Sell at Zacks Investment Research - Ticker Report | 7/17/2020

Precision BioSciences (NASDAQ:DTIL) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in …

LogicBio Therapeutics (NASDAQ:LOGC) Rating Lowered to Hold at Zacks Investment Research - Dakota Financial News | 7/17/2020

LogicBio Therapeutics (NASDAQ:LOGC) was downgraded “buy” note issued to investors “LogicBio Therapeutics Inc. is a genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The company’s technology platform consists of GeneRide(TM). LogicBio Therapeutics Inc. is based in Cambridge, Massachusetts. “ Several other research firms also recently issued reports on LOGC. William Blair restated a “buy” rating on shares of …

Global Genome Engineering Market Foreseen to Exceed the US$ 8,512.5 Million Threshold by 2025 - Coherent Market Insights | 7/17/2020

… rapidly modifies difficult-to-edit human hematopoietic stem cells, as well as primary T cells, in a cost-effective manner. In 2017, Thermo Fisher Scientific–a U.S.-based player– launched its expanded Invitrogen TrueEdit genome editing toolkit, which was designed to address the full spectrum of genome editing needs. In January 2018, Synthego Corporation introduced its new CRISPR Analysis Software, Inference of CRISPR Edits (ICE) into the global market. Thus …

Targeted Genome Editing of Bacteria Within Microbial Communities | 7/17/2020

… Cas Transposase (DART) systems for targeted DNA insertion into organisms identified as tractable by ET-Seq, enabling organism- and locus-specific genetic manipulation within the community context. These results demonstrate a strategy for targeted genome editing of specific organisms within microbial communities, establishing a new paradigm for microbial manipulation relevant to research and applications in human, environmental, and industrial microbiomes. Regents of the University of California have patents pending related …

CRISPR Gene/Genome Editing Life Sciences in North America & Europe, 2020 - Developed from Responses to a 29-Question Survey Completed by 368 Scientists | PR Newswire | 7/16/2020

CRISPR Gene/Genome Editing Life Sciences in North America & Europe, 2020 - Developed from Responses to a 29-Question Survey Completed by 368 Scientists News provided by Jul 16, 2020, 10:45 ET Share this article DUBLIN , July 16, 2020 /PRNewswire/ – The “2020 CRISPR Gene/Genome Editing Life Science Dashboard Series 1 - NA & EU” report has been added to ResearchAndMarkets.com’s offering. As life science suppliers continue to improve products and services the …

Cas9 fusions for precision in vivo editing | 7/16/2020

Current Cas9 reagents can target genomic loci with high specificity. However, when used for knockin, on-target outcomes are inherently imprecise, often leading to unintended knockout rather than intended edits. This restricts applications of genome editing to ex vivo approaches, where clonal selection is possible. Here we describe a workflow using iterative high-throughput in vitro and high-yield in vivo assays to evaluate and compare the performance of CRISPR …

Recently discovered CRISPR enzyme from huge bacteriophages expands genome editing toolbox | 7/16/2020

A recently discovered hypercompact CRISPR enzyme found only in huge bacteriophages, and known as CRISPR-CasΦ, is functional, a new study by Patrick Pausch, Jennifer Doudna and colleagues reports, and it provides a powerful new tool in the CRISPR genome editing toolbox, including because it can target a wider range of genetic sequences compared to Cas9 and Cas12. The authors tested its target-expanding capabilities in human and plant cells …

CRISPR-Cas(Phi) from huge phages is a hypercompact genome editor | 7/16/2020

The CRISPR-Cas system, naturally found in many prokaryotes, is widely used for genome editing . CRISPR arrays in the bacterial genome, derived from the genome of invading viruses, are used to generate a CRISPR RNA that guides the Cas enzyme to destroy repeat viral invaders. Recently, an unexpectedly compact CRISPR-Cas system was identified in huge bacteriophages. Pausch et al . show that even though this system lacks commonly found accessory …

Sustainable farming? GMOs? Agroecology? Be a part of the discussion | 7/16/2020

Sustainable farming? GMOs? Agroecology? Be a part of the discussion By - July 16, 2020 Our upcoming webinar Sense, Science and Sustainability is asking a hot topic question: Can genome editing and agroecology co-exist in the sustainable food and farming mix? The UK government is currently debating an amendment to the Agriculture Bill that would change the Environmental Protection Act and deregulate gene edited organisms in England, and possibly the …

Huge virus’s mini-enzymes boost CRISPR’s powers | 7/16/2020

A CRISPR–Cas complex (purple and orange) edits a strand of DNA (green). An ultrasmall version of the Cas enzyme that cuts the DNA could make editing easier. Credit: Getty CRISPR-Cas9 genome editing 16 July 2020 Huge virus’s mini-enzymes boost CRISPR’s powers The viruses called Biggiephages harbour compact enzymes that can target a broad range of DNA sequences. Unusually small enzymes from extra-large viruses allow the CRISPR …

Cover-all Induced Pluripotent Stem Cells Services Are Optimized at Creative Biolabs | 7/15/2020

… in stem cell services, Creative Biolabs has upgraded its cover-all induced pluripotent stem cell services to facilitate global scientists with related research, including iPSC differentiation, iPSC reprogramming, cell-based organoid services and iPSC genome editing services. New York, United States – July 15, 2020 /MarketersMedia/ — In recent years, investigators turn their focuses on induced pluripotent stem cells (iPSCs). The idea that a patient’s tissues could transform into a copious, immune …

NA & EU CRISPR Gene/Genome Editing Life Science Market Dashboard, 2020 | Globe Newswire | 7/15/2020

Dublin, The “2020 CRISPR Gene/Genome Editing Life Science Dashboard Series 1 - NA & EU” report has been added to ResearchAndMarkets.com’s offering. As life science suppliers continue to improve products and services the CRISPR gene/genome editing market, represents a significant opportunity within the life sciences industry. The 2020 CRISPR Gene/Genome Editing Life Science Dashboard is the first in a series that characterizes the dynamic market for products for CRISPR …

Ten innovations that can improve global health | 7/15/2020

… These technologies—key components of the Bio Revolution —are therapeutics or diagnostics that harness the various types of molecules within cells (such as DNA, RNA, and proteins). Some omics and molecular technologies (for instance, genome editing ) engineer these intracellular components or analyze them (such as proteomics and transcriptomics). Example: CRISPR and curbing malaria The current treatment includes antimalarial prophylactics and nonpharmaceutical measures (such as indoor residual spraying and insecticide-treated …

A positive, growth-based PAM screen identifies noncanonical motifs recognized by the S. pyogenes Cas9 | 7/15/2020

… between the target and canonical PAM. More direct experiments will be required to assess the prevalence of this phenomenon across Cas9s and other CRISPR nucleases and whether it applies to nucleases commonly used for genome editing and other applications ( 4 ). The standard visualization schemes for PAM screens (e.g., sequence logo, PAM wheel) can also mask shifted PAMs, although this could be remedied by supplementing the visualization scheme with motif plots …

Matt Ridley: How Innovation Works, Part 2 | 7/15/2020

… it’s almost too late.” It’s very hard to see how Europe now changes its minds and adopts this new technology. The best hope is that with the next technology that comes along, which is genome editing through things like CRISPR, a lot of the concerns of environmentalists can be set to one side because this is not a technology that involves bringing foreign genetic material from other creatures, whatever that …

Coronavirus (COVID-19) Impact on Genome Editing Techniques Market 2020 by Manufacturers, Type and Application, Forecast to 2025 | 7/15/2020

This report also researches and evaluates the impact of Covid-19 outbreak on the Genome Editing Techniques industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Genome Editing Techniques and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.). Scope of the Report: The report presents the market outlook for the Indian Phospho Gypsum product …

CRISPR

Doudna’s team identifies new ‘hypercompact’ CRISPR enzyme | FierceBiotech | 7/17/2020

The CRISPR-Cas system has proven to be an extremely powerful gene-editing tool, but it has several limitations for clinical applications. For one thing, it’s difficult to deliver the material into cells efficiently because … to the researchers. The team showed CRISPR-CasΦ can perform genome editing in both human and plant cells. In one case, a variant of CasΦ was able to edit up to 33% of human cells …

Genomics

Gene-editing discovery could point the way toward a ‘holy grail’: cures for mitochondrial diseases | STAT | 7/8/2020

… for a technology like this for a very long time,” said biologist Fyodor Urnov of the University of California’s Innovative Genomics Institute, who reviewed the paper for Nature. “We’ve been able to make point mutations … muscles and brains, and eventually take their lives. advertisement The genome editing revolution has largely passed mitochondria by. CRISPR doesn’t work: The guide RNA it uses like a bloodhound to find its target within a …

COVID-19

COVID-19 Impact and Recovery Analysis - Global Synthetic Biology Market 2020-2024 | Evolving Opportunities with Amyris Inc. and Algenol | Technavio | Business Wire | 7/1/2020

… per Technavio. This marks a significant market growth compared to the 2019 growth estimates due to the impact of the COVID-19 pandemic in the first half of 2020. Healthy growth is expected to continue … genomic applications. Some of these products include DNA & RNA, CRISPR genome editing, next-generation sequencing products, genes & gene fragments, qPCR & PCR primers, GMP, OEM & integrations, and IDT Oligo card. Register for a free trial today …

Big Pharma

GlaxoSmithKline pens $120M upfront synthetic lethality cancer pact with Ideaya | FierceBiotech | 6/16/2020

… 2016 with a $46 million series A round that set it up to run synthetic lethality screens. That entails using genome editing tools to identify pairs of mutations that, when hit simultaneously, lead to cell … The drug is small-molecule PKC inhibitor licensed from Swiss Big Pharma Novartis. Now, and once more after a quiet period, it’s nabbed a new pact with GSK centered on its early-stage lethality programs …

Hematology

Streamlined and scalable CHANGE-Seq method improves understanding of genome editors | Phys Org | 6/16/2020

… CHANGE-seq). The work appears as an advance online publication today in Nature Biotechnology . CRISPR-Cas nucleases are a transformative genome editing technology that has become broadly adopted for research and is being studied as … nucleases,” said corresponding author Shengdar Tsai, Ph.D., of St. Jude Hematology. “With this method, scientists can now rapidly pick the best and safest genome editors and targets for therapeutic editing, such as for treatment of …

CDC

U.S. Secretary of Agriculture Sonny Perdue and Pairwise Leaders Discuss Food Solutions to Health Challenges | Business Wire | 6/16/2020

… adults are getting the recommended daily allowance of fruits and vegetables, accordingly to the Centers for Disease Control and Prevention (CDC). Only eight percent of calories in the average U.S. diet come from fruit and … nutritious food on tables across North America. From developing novel genome editing tools to leveraging the natural genetic diversity of plants to creating robust partnerships and collaborations, Pairwise is addressing the biggest challenges facing the …

National Institutes of Health

Precision genome editing enters the modern era | Phys Org | 6/15/2020

CRISPR has sparked a renaissance in genome editing. Now, next-generation CRISPR technologies let scientists modify the genome more efficiently and precisely than before. Such tools could one day serve as therapeutics, but many challenges … term study that Liu’s team and their collaborators at the National Institutes of Health and Vanderbilt University are still wrapping up. But he calls the results so far “incredibly exciting.” Credit: Howard Hughes Medical Institute …

Biotech

Epsilen Bio appoints Julia Berretta as Chief Executive Officer and Mathieu Simon as Chairman of the Board | Business & Finance | heraldchronicle.com | Business Wire | 6/15/2020

MILAN–(BUSINESS WIRE)–Jun 15, 2020– Epsilen Bio , a biotechnology company developing transformative therapies for patients affected by underserved medical conditions through stable epigenetic silencing of genes involved in pathological processes, announced today the appointments … silencing technology with the group of Epigenetic Regulation and Targeted Genome Editing led by Dr. Angelo Lombardo, and exclusively in-licensed by Epsilen Bio. The announcements follow the successful close of a seed financing of …

Gene Therapy

Epsilen Bio appoints Julia Berretta as Chief Executive Officer and Mathieu Simon as Chairman of the Board | Business Wire | 6/15/2020

Gene Therapy (SR-Tiget), a world-renowned research center devoted to gene therapy, directed by Professor Luigi Naldini. Within the collaboration Epsilen Bio will further develop the epigenetic silencing technology with the group of Epigenetic Regulation and Targeted Genome Editing led by Dr. Angelo Lombardo, and exclusively in-licensed by Epsilen Bio. The announcements follow the successful close of a seed financing of €2.3 million from Sofinnova Partners, a leading …

CAR-T

Epsilen Bio appoints Julia Berretta as Chief Executive Officer and Mathieu Simon as Chairman of the Board | Business & Finance | heraldchronicle.com | Business Wire | 6/15/2020

… Within the collaboration Epsilen Bio will further develop the epigenetic silencing technology with the group of Epigenetic Regulation and Targeted Genome Editing led by Dr. Angelo Lombardo, and exclusively in-licensed by Epsilen Bio. The … S.A., a Nasdaq-listed clinical stage gene editing company developing CAR-T cell therapies for cancer, where she led business development as well as strategic planning. Dr. Simon is Chairman of the Board of Idorsia …

Food and Drug Administration

Sherlock Biosciences and Integrated DNA Technologies (IDT) Announce Strategic Partnership for Manufacturing CRISPR SARS-CoV-2 Diagnostic and Research Products | Business Wire | 6/8/2020

… that causes COVID-19. The test kit, for which Sherlock Biosciences recently received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA), will assist in managing the COVID-19 pandemic by increasing … technologies for genomics applications such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. Through its GMP services, IDT manufactures products used by scientists in researching many forms of cancer …

Precision Medicine

LabRoots’ Genetics Virtual Week Announces Three-Day Agenda for 2020 Event, Dedicated to Advancing Best Practices in Genomics, Molecular Diagnostics and Precision Medicine | PRWeb | 4/14/2020

… Genetics Virtual Week Announces Three-Day Agenda for 2020 Event, Dedicated to Advancing Best Practices in Genomics, Molecular Diagnostics and Precision Medicine Share Article GVW’s mission is to bring together innovators across healthcare and biomedical … look spanning three days with three core focuses, sessions comprise: Genome Editing The Evolution of Genome Reference Concepts Single Cell and Spatial Genomics Structural Variation Rare Disease in Precision Medicine Precision Medicine in Clinic Molecular …

Clinical Research

Is China Effectively Reforming Its Biotechnology Laws? | 12/6/2019

clinical research are coming into force, but do they mean real change for the country? New Rules as Part of China’s Biotechnology Strategy On top of Beijing’s existing prohibitions against reproductive human genome editing, the Chinese Health Ministry has published draft regulations outlining new criminal charges for genetically engineering humans. In April, the government further elevated the matter of human genetics to the high-water mark of fundamental rights, announcing …

NIH

CRISPR/CAS Gene Editing in Vivo Postdoctoral Position | Nature | 12/4/2019

NIH Somatic Cell Genome Editing consortium ( https://scge.mcw.edu/ ). The project will design and evaluate new delivery systems for genome editing tools in mice and large animal models. The position’s primary focus is to evaluate the on-target and off-target activities of genetic and epigenetic editing tools. The successful candidate is expected to prepare and submit manuscripts to peer-reviewed journals, and participate in seminars and weekly lab meetings. Qualifications …

UC Davis

CRISPR/CAS Gene Editing in Vivo Postdoctoral Position | Nature | 12/4/2019

… UC Davis) Davis, CA, United States Posted about 52 minutes ago Expires on January 21, 2020 Description: A postdoctoral position is available for a joint project between the laboratories of: Dr. Kit Lam ( https://basicscience.ucdmc.ucdavis.edu/Lam_Lab/ ), Dr. R. Holland Chang ( https://biology.ucdavis.edu/people/rholland-cheng ) Dr. David J. Segal ( https://biology.ucdavis.edu/people/david-segal ), supported by the NIH Somatic Cell Genome Editing consortium ( https://scge.mcw.edu/ ). The project will design …

Rice University

Why the paper on the CRISPR babies stayed secret for so long - MIT Technology Review | 12/3/2019

… last December, and his original team of 10 has scattered to the four winds. An American collaborator, Michael Deem of Rice University, is the subject of an investigation by that institution; it has come to … he’d prepared a scientific manuscript, titled “Birth of Twins After Genome Editing for HIV Resistance.” As he slept, he might have dreamed of being toasted for a medical first and seeing his name on a …

Regenerative Medicine

Stem Cell Technology: The Only Constant Is Change | 12/2/2019

… the development of reprogramming techniques and the generation of induced pluripotent stem cells (iPSCs). More recently, advances in biotechnology and genome editing have fostered a modern evolution of stem cell advances that shows no signs … reputable scientists and regulatory authorities, people eager to benefit from regenerative medicine may seek care from stem cell clinics, if not for themselves, then for their beloved pets. For example, dog owners may be attracted …

Medical Research

Genome Editing Services Market-Focus on CRISPR, 2019-2030 | PR Newswire | 11/28/2019

Genome Editing Services Market-Focus on CRISPR, 2019-2030 News provided by Nov 28, 2019, 08:00 ET NEW YORK , Nov. 28, 2019 /PRNewswire/ – INTRODUCTION The 1970s witnessed the introduction of one of the most revolutionary advances … regularly interspaced short palindromic repeats (CRISPR). These developments have enabled medical researchers to perform an array of gene / cell line engineering experiments, including gene knockdowns, gene overexpressions and single base editing, for a variety of …

RNA Sequencing

Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity | 11/28/2019

… CTL medium containing different serum supplements, all in vitro functional assays were performed in CTL medium supplemented with 10% FBS. Genome editing of the CCR7 gene in T cells Guide RNA for the CCR7 gene … CA) and quantified using the NanoDrop 2000 (Thermo Fisher Scientific). RNA sequencing and analysis were performed by Novogene Corporation (Sacramento, CA). Heat map was generated using Heatmapper [ 30 ] . 51 Chromium-release assay The cytotoxicity and …

Clinical Data

New frontiers to cure Alport syndrome: COL4A3 and COL4A5 gene editing in podocyte-lineage cells | Nature | 11/21/2019

… we employed a two-plasmid approach in order to achieve a beneficial and stable variant-specific correction using CRISPR/Cas9 genome editing. One plasmid carries a Donor DNA and a reporter system mCherry/GFP to … in males with an X-linked form of the disease. Clinical data and variants were submitted to the Leiden Open Variation Database LOVD, www.lovd.nl/COL4A5 (Individual ID 00245760). Patient 2 (3459/18ats) : The patient is affected …

Mental Health

Preliminary Data Shows CRISPR Benefits Patients With Devastating Sickle Cell Disease, Other Blood Disorders | Kaiser Health News | 11/20/2019

genome editing might one day offer a safe, durable cure for both blood diseases. (Begley and Feuerstein, 11/19) The Associated Press: Hospital Psychiatric Wards Now Feel Like Prisons, Some Say Hospitals have been overhauling facilities and procedures in psychiatric wards nationwide in response to new guidelines for suicide prevention. Some mental health advocates and officials say the changes have come at the expense of patient privacy and dignity, making mental …

Medicare

12 burning questions for Stephen Hahn, Trump’s pick to lead FDA | STAT | 11/20/2019

… planting radioactive seeds meant to treat prostate cancer into veterans. Another controversy almost got MD Anderson kicked out of the Medicare program. The third left Hahn assuring his colleagues he did not racially target scientists … cells growing in lab dishes have found that CRISPR-based genome editing can alter DNA in ways that could raise the risk of cancer and other serious diseases — but, in all likelihood, not for years …

ISTH

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/7/2019

… whatever technology is best suited to deliver that treatment, including gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing and in vivo gene regulation. As we move ahead with a robust pipeline … will recall that our last data follow-up was at ISTH in July 2019 where we showed data from the first four subjects at the high dose, 313, [indiscernible] had been followed for 24 weeks …

Clinical Operations

Non-Clinical Operations Coordinator - Cambridge, MA, , USA #jobs #Cambridge pls RT | 10/30/2019

Job Detail for Non-Clinical Operations Coordinator Job Location: Intellia Therapeutics, Cambridge, MA, , USA Job Detail for Non-Clinical Operations Coordinator Job Location: Intellia Therapeutics, Cambridge, MA, , USA Jobs In Non Clinical Operations Coord… Jobs In Non Clinical O… Jobs In Non Clini… At Intellia, we are revolutionizing medicine by harnessing the power of genome editing to develop potential cures. We bring new hope for people living with conditions including …

University of Missouri

Research team wants to eliminate dangerous plant diseases in rice | Phys Org | 10/28/2019

… bacterium to divide by preventing it from hijacking the plant’s resources as food supply ,” explains Dr. Bing Yang from the University of Missouri. To understand this, they used their knowledge of how the Xoo bacteria … y Broad-spectrum resistance to bacterial blight in rice using genome editing, Nature Biotechnology (2019). DOI: 10.1038/s41587-019-0267-z , https://nature.com/articles/s41587-019-0267-z Nature Biotechnology Provided by Heinrich-Heine University Duesseldorf Citation : Research team …

Beam Therapeutics

This Startup Might Finally Cure Sickle Cell Disease—After A Century Of Racist Neglect | Forbes | 7/10/2020

… blood disorder, which mostly affects Black people, is just one of thousands of rare diseases that could be cured by Beam Therapeutics’ revolutionary gene editing technology. B eam Therapeutics CEO John Evans loves rocket launches … the years ahead. “The stuff we can do now in genome editing would have seemed like magic five or ten years ago,” he says, as technological advancements suddenly have biotechs competing to cure rare genetic …

Gilead Sciences

Gilead axes $445M Precision Biosciences gene therapy hep B pact | FierceBiotech | 7/8/2020

Gilead Sciences is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact. Back in September 2018, Gilead laid up to $445 million on the table in biobucks that saw the pair collaborate on gene therapies aimed at eliminating viral infections in vivo by using Precision’s genome editing platform. Under the deal, Gilead was on tap to …

Precision BioSciences

Gilead axes $445M Precision Biosciences gene therapy hep B pact | FierceBiotech | 7/8/2020

Gilead Sciences is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact. Back in September 2018, Gilead laid up to $445 million on the table in biobucks that saw the pair collaborate on gene therapies aimed at eliminating viral infections in vivo by using Precision’s genome editing platform. Under the deal, Gilead was on tap to …

Gilead

Gilead axes $445M Precision Biosciences gene therapy hep B pact | FierceBiotech | 7/8/2020

Gilead Sciences is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact. Back in September 2018, Gilead laid up to $445 million on the table in biobucks that saw the pair collaborate on gene therapies aimed at eliminating viral infections in vivo by using Precision’s genome editing platform. Under the deal, Gilead was on tap to …

Merck

Worldwide CRISPR Market to 2028 - Key Drivers, Restraints, Opportunities and Challenges | PR Newswire | 6/26/2020

… Addgene, Origene Technologies Inc, Genedata AG, Intellia Therapeutics Inc, Cellectis, Applied StemCell, Transposagen Bio (Hera BioLabs), GeneCopoeia Inc, Sigma-Aldrich (Merck KGaA), DiaCarta, Editas Medicine, New England Biolabs, Sangamo Therapeutics, GenScript, Thermo Fisher Scientific Inc … 3.8. Other Products 4. CRISPR Market Outlook - By Application 4.1. Genome Editing/Genetic Engineering 4.1.1. Genetically Modified Organisms 4.1.2. Agricultural Biotechnology 4.1.3. Other Genome Editing/Genetic Engineering 4.2. Grna Database/Gene Library 4.3. CRISPR Plasmid …

Thermo Fisher

Worldwide CRISPR Market to 2028 - Key Drivers, Restraints, Opportunities and Challenges | PR Newswire | 6/26/2020

… StemCell, Transposagen Bio (Hera BioLabs), GeneCopoeia Inc, Sigma-Aldrich (Merck KGaA), DiaCarta, Editas Medicine, New England Biolabs, Sangamo Therapeutics, GenScript, Thermo Fisher Scientific Inc and CRISPR Therapeutics. Applied StemCell is a company that aims at … 3.8. Other Products 4. CRISPR Market Outlook - By Application 4.1. Genome Editing/Genetic Engineering 4.1.1. Genetically Modified Organisms 4.1.2. Agricultural Biotechnology 4.1.3. Other Genome Editing/Genetic Engineering 4.2. Grna Database/Gene Library 4.3. CRISPR Plasmid …

Sangamo Therapeutics

Worldwide CRISPR Market to 2028 - Key Drivers, Restraints, Opportunities and Challenges | PR Newswire | 6/26/2020

… Inc, Cellectis, Applied StemCell, Transposagen Bio (Hera BioLabs), GeneCopoeia Inc, Sigma-Aldrich (Merck KGaA), DiaCarta, Editas Medicine, New England Biolabs, Sangamo Therapeutics, GenScript, Thermo Fisher Scientific Inc and CRISPR Therapeutics. Applied StemCell is a company … 3.8. Other Products 4. CRISPR Market Outlook - By Application 4.1. Genome Editing/Genetic Engineering 4.1.1. Genetically Modified Organisms 4.1.2. Agricultural Biotechnology 4.1.3. Other Genome Editing/Genetic Engineering 4.2. Grna Database/Gene Library 4.3. CRISPR Plasmid …

Intellia Therapeutics

Worldwide CRISPR Market to 2028 - Key Drivers, Restraints, Opportunities and Challenges | PR Newswire | 6/26/2020

… are Horizon Discovery Ltd, Integrated DNA Technologies Inc, Caribou Biosciences Inc, Precision Biosciences, Lonza, Addgene, Origene Technologies Inc, Genedata AG, Intellia Therapeutics Inc, Cellectis, Applied StemCell, Transposagen Bio (Hera BioLabs), GeneCopoeia Inc, Sigma-Aldrich (Merck … 3.8. Other Products 4. CRISPR Market Outlook - By Application 4.1. Genome Editing/Genetic Engineering 4.1.1. Genetically Modified Organisms 4.1.2. Agricultural Biotechnology 4.1.3. Other Genome Editing/Genetic Engineering 4.2. Grna Database/Gene Library 4.3. CRISPR Plasmid …

Thermo Fisher Scientific

Worldwide CRISPR Market to 2028 - Key Drivers, Restraints, Opportunities and Challenges | PR Newswire | 6/26/2020

… StemCell, Transposagen Bio (Hera BioLabs), GeneCopoeia Inc, Sigma-Aldrich (Merck KGaA), DiaCarta, Editas Medicine, New England Biolabs, Sangamo Therapeutics, GenScript, Thermo Fisher Scientific Inc and CRISPR Therapeutics. Applied StemCell is a company that aims at … 3.8. Other Products 4. CRISPR Market Outlook - By Application 4.1. Genome Editing/Genetic Engineering 4.1.1. Genetically Modified Organisms 4.1.2. Agricultural Biotechnology 4.1.3. Other Genome Editing/Genetic Engineering 4.2. Grna Database/Gene Library 4.3. CRISPR Plasmid …

Pfizer

Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy | Business Wire | 6/18/2020

NEW YORK & BRISBANE, Calif.- Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525 … therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit www.sangamo.com . About Pfizer Rare Disease Rare diseases include some of the most serious of …

Celgene

GlaxoSmithKline pens $120M upfront synthetic lethality cancer pact with Ideaya | FierceBiotech | 6/16/2020

… 2016 with a $46 million series A round that set it up to run synthetic lethality screens. That entails using genome editing tools to identify pairs of mutations that, when hit simultaneously, lead to cell … already dotted with big names such as 5AM Ventures and Celgene. A year later, it wrapped up a $50 million IPO and later nabbed an FDA IND for its clinical effort IDE196, which is being …

Novartis

GlaxoSmithKline pens $120M upfront synthetic lethality cancer pact with Ideaya | FierceBiotech | 6/16/2020

… 2016 with a $46 million series A round that set it up to run synthetic lethality screens. That entails using genome editing tools to identify pairs of mutations that, when hit simultaneously, lead to cell … is small-molecule PKC inhibitor licensed from Swiss Big Pharma Novartis. Now, and once more after a quiet period, it’s nabbed a new pact with GSK centered on its early-stage lethality programs MAT2A, Pol …

GlaxoSmithKline

GlaxoSmithKline pens $120M upfront synthetic lethality cancer pact with Ideaya | FierceBiotech | 6/16/2020

As GlaxoSmithKline looks to deepen its cancer R&D, it’s penned an oncology development program with Ideaya Biosciences. South San Francisco-based Ideaya broke cover in 2016 with a $46 million series A round that set it up to run synthetic lethality screens. That entails using genome editing tools to identify pairs of mutations that, when hit simultaneously, lead to cell death. PARP inhibitors such as AstraZeneca’s Lynparza and Clovis …

AstraZeneca

GlaxoSmithKline pens $120M upfront synthetic lethality cancer pact with Ideaya | FierceBiotech | 6/16/2020

As GlaxoSmithKline looks to deepen its cancer R&D, it’s penned an oncology development program with Ideaya Biosciences. South San Francisco-based Ideaya broke cover in 2016 with a $46 million series A round that set it up to run synthetic lethality screens. That entails using genome editing tools to identify pairs of mutations that, when hit simultaneously, lead to cell death. PARP inhibitors such as AstraZeneca’s Lynparza and Clovis …

LogicBio Therapeutics

LogicBio Therapeutics to Hold Virtual-Only Annual Meeting of Stockholders Nasdaq:LOGC | Globe Newswire | 6/5/2020

LEXINGTON, Mass., June 05, LogicBio Therapeutics, Inc. (Nasdaq: LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced that its 2020 Annual Meeting of Stockholders (2020 Annual Meeting) will be held in a virtual-only format due to continued public health concerns related to coronavirus / COVID-19, and to support the health and well-being of our …

GSK

FiercePharmaAsia—CanSino’s COVID-19 vaccine data; Takeda’s new Alunbrig nod; GSK-Samsung deal | FiercePharma | 5/29/2020

… years. The deal will initially cover lupus drug Benlysta and could expand to other products. Possible candidates could come from GSK’s cancer pipeline, including the anti-BCMA antibody-drug conjugate belantamab mafodotin that’s under FDA … EdiGene pairs with Immunochina to develop CAR-T Therapy (release) Genome editing specialist EdiGene formed an R&D collaboration with Immunochina to develop CAR-T therapies for cancer. EdiGene has gene-editing platforms for hematopoietic …

Allergan

Editas’ (EDIT) Earnings Beat in Q1, Revenues Improve Y/Y | Zacks | 5/8/2020

… development revenues. Its collaboration revenues increased in the first quarter owing to higher collaboration payments recognized under its collaboration with Allergan ( AGN - Free Report ) . In the reported quarter, research and development expenses were $34.6 million … option agreement with Sandhill Therapeutics, Inc., to combine their respective genome editing and cell therapy technologies for discovering and developing allogeneic engineered NKcells and non-alpha beta T cell medicines to treat cancer. Editas Medicine …

Vertex Pharmaceuticals

Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer | Globe Newswire | 4/30/2020

… efforts using stem-cell-derived pancreatic islets to cure type I diabetes starting in November 2018. Semma was acquired by Vertex Pharmaceuticals Inc., in October 2019. Prior to his role at Semma, Dr. Lebwohl held … leadership team as we propel the first systemic CRISPR/Cas9 genome editing treatment to the clinic this year,” said Dr. Lebwohl. “I am passionate about working on the next generation of treatments, like genome editing

WebMD

The next pandemic could be even worse (Opinion) - CNN | 4/29/2020

Jamie Metzl is a member of the World Health Organization international advisory committee on human genome editing, a former National Security Council official and author of “ Hacking Darwin: Genetic Engineering and the Future of Humanity. “ Andrew Hessel is the chairman of the Genome Project-write and the president of Humane Genomics. Hansa Bhargava, MD, is a senior medical director at WebMD and MedScape. The opinions expressed in this commentary are …

Abbott Laboratories

Pre & Post COVID-19 Market Estimates-Global Biotechnology Reagents Market 2020-2024 | Evolving Opportunities with Abbott Laboratories and Agilent Technologies Inc. | Technavio | Business Wire | 4/18/2020

… availability of novel technologies such as highly personalized and predictive throughput screening, pre-disease and biomarker identification, gene therapy and genome editing for earlier disease detection, and rapid POC diagnostics is driving the demand for … get the third for free. Major Five Biotechnology Reagents Companies: Abbott Laboratories Abbott Laboratories has business operations under various segments, such as established pharmaceuticals products, nutritional products, diagnostic products, and medical devices. The company’s key …

Qiagen

2020 Agricultural Biotechnology Market Study, Featuring Profiles of 96 Companies Including Ajinomoto, BASF, Cibus, Novozymes, Oxford Nanopore Technologies, and Qiagen | PR Newswire | 3/25/2020

2020 Agricultural Biotechnology Market Study, Featuring Profiles of 96 Companies Including Ajinomoto, BASF, Cibus, Novozymes, Oxford Nanopore Technologies, and Qiagen News provided by Mar 25, 2020, 12:15 ET Share this article DUBLIN , March 25, 2020 … generation DNA sequencing, biochips, RNA interference, synthetic biology tools and genome editing tools, and assaying their role in enhancing the marketplace Underlying market opportunities for biotechnology tools, genomic-enabled products, and biotech seeds enhancing growth …

ImmunoGen

LogicBio Therapeutics Appoints Mark Enyedy to its Board of Directors | Globe Newswire | 3/16/2020

genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced that Mark Enyedy has been appointed to its Board of Directors, effective as of March 17, 2020. Mr. Enyedy, who brings over 25 years of deep experience in biotech management, strategy, and corporate development, currently serves as President and Chief Executive Officer of Immunogen, Inc. Tomer Kariv, Esq., co-founder and Chief Executive …

GE Healthcare

CRISPR & CRISPR-associated (Cas) Genes Market Outlook to 2027 | GE Healthcare, Koninklijke Philips N.V., Cardinal Health, Halma, MasimoHillrom Holdings | 12/2/2019

… GE Healthcare, Koninklijke Philips N.V., Cardinal Health, Halma, MasimoHillrom Holdings The report on “CRISPR & CRISPR-associated (Cas) Genes Market” will help Major Players and the new entrants to understand scrutinize the market in detail. This information will encourage the Major Players to decide their business strategy and achieve proposed business aims. CRISPR and CRISPR-Associated (Cas) Genes is a genome editing tool that enables the researchers to make changes in …

Johnson & Johnson

Cyrus, the Broad team up to make in vivo CRISPR use safer | FierceBiotech | 12/2/2019

genome editing stems from the risk that the body will mount an immune response against the system. Those concerns have grown as researchers have shown that many people have antibodies against Cas9, reflecting the fact that the homologs of the protein used in genome editing systems are derived from bacteria that commonly infect people. Cyrus, which lists Johnson & Johnson among its customers, thinks its technology can mitigate the risk of …

Regeneron Pharmaceuticals

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool | PR Newswire | 11/28/2019

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool News provided by Research and Markets Nov 28, 2019, 07:00 ET DUBLIN , Nov. 28, 2019 /PRNewswire/ – The “Genome Editing Services Market-Focus on CRISPR 2019-2030” report has been added to ResearchAndMarkets.com’s offering. This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an …

Morgan Stanley

Editas Medicine Announces Closing of Offering of Common Stock and Full Exercise by Underwriter of Option to Purchase Additional Shares Nasdaq:EDIT | Globe Newswire | 6/26/2020

CAMBRIDGE, Mass., Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the closing of its previously announced underwritten offering of 6,900,000 shares of its common stock at a public offering price of … the shares in the offering were sold by Editas Medicine. Morgan Stanley acted as sole book-running manager for the offering. A registration statement on Form S-3 (including a preliminary prospectus describing the terms …

Editas Medicine Announces Pricing of Offering of Common Stock | Globe Newswire | 6/24/2020

CAMBRIDGE, Mass., June 23, Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the pricing of an underwritten offering of 6,000,000 shares of its common stock at a public offering price of … or about June 26, 2020, subject to customary closing conditions. Morgan Stanley is acting as sole book-running manager for the offering. A registration statement on Form S-3 (including a preliminary prospectus describing the …

Zacks Equity Research

Editas’ (EDIT) Earnings Beat in Q1, Revenues Improve Y/Y | Zacks | 5/8/2020

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Editas Medicine, Inc. ( EDIT - Free Report ) incurred a loss … option agreement with Sandhill Therapeutics, Inc., to combine their respective genome editing and cell therapy technologies for discovering and developing allogeneic engineered NKcells and non-alpha beta T cell medicines to treat cancer. Editas Medicine …

Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates | Zacks | 11/12/2019

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Editas Medicine ( EDIT - Free Report ) came out … of 9.59%. A quarter ago, it was expected that this genome editing company would post a loss of $0.59 per share when it actually produced a loss of $0.69, delivering a surprise of -16.95%. Over …

Wellcome Trust

Postdoctoral researcher in cell biology | Nature | 11/21/2019

… Wellcome Trust-funded postdoctoral position in cell biology is available in the laboratory of Dr Anthony Roberts. The Roberts Lab is investigating the microtubule-based motor proteins that drive the construction and signalling functions of cilia/flagella. This project involves combining mammalian cell culture, genome editing, and high-resolution fluorescence microscopy to understand the coordination of intraflagellar transport dynein and kinesin in mammalian cells. For further information, please see Toropova …

Research Assistant | Nature | 11/24/2017

… Department of Medicine, University of Cambridge but the project will also involve collaborating with colleagues at other institutes including the Wellcome Trust Sanger Institute and the Laboratory of Molecular Biology ( LMB ). The post will involve … plasma membrane profiling by mass spectrometry, RNA and DNA extraction, genome editing, flow cytometry and setting up/assessing in vivo models. The successful candidate will have a degree (or equivalent) in a relevant subject, together …

Guggenheim Securities

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/7/2019

… Head of Corporate Strategy Sung Lee - Chief Financial Officer Conference Call Participants Maury Raycroft - Jefferies Gena Wang - Barclays Whitney Ijem - Guggenheim Securities Ritu Baral - Cowen Eric Joseph - JPMorgan Yanan Zhu - Wells Fargo Securities Operator Good … gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing and in vivo gene regulation. As we move ahead with a robust pipeline of genomic medicines across these various platforms, we understand that …

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/9/2019

… Ed Conner - Chief Medical Officer Ed Rebar - Chief Technology Officer Kathy Yi - Chief Financial Officer Conference Call Participants Evan Wang - Guggenheim Securities Xiaobin Gao - Barclays Ritu Baral - Cowen Yanan Zhu - Wells Fargo Securities Jim Birchenough … medicines pipeline encompasses four complementary approaches, gene therapy, ex vivo genome editing and gene regulation. We are developing products for conditions for the suite of proprietary genomic medicine technologies has the potential to make a …

NCI

Molecular Combing to Be Used by NIH’s Scientists as a Tool for Cancer Research and Drug Screening – Company Announcement - FT.com | Financial Times | 9/25/2019

… modified genome, announce the acquisition of the molecular combing platform by the Developmental Therapeutics Branch at the National Cancer Institute (NCI) within the NIH based in Bethesda. The FiberComb ® and FiberVision ® are going to be … quality and safety of genetically modified genome in particular in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary molecular tools provide robust quantitative measurements that are needed to enable high confidence characterization of DNA …

Molecular Combing to Be Used by NIH’s Scientists as a Tool for Cancer Research and Drug Screening | Business Wire | 9/25/2019

… modified genome, announce the acquisition of the molecular combing platform by the Developmental Therapeutics Branch at the National Cancer Institute (NCI) within the NIH based in Bethesda. The FiberComb ® and FiberVision ® are going to be … quality and safety of genetically modified genome in particular in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary molecular tools provide robust quantitative measurements that are needed to enable high confidence characterization of DNA …

Oxford Finance

SGI-DNA Secures $25 Million Series A Financing to Support Commercial Launch | Business Wire | 9/9/2019

… DNA data storage solutions, has completed a $25 million Series A financing round led by Northpond Ventures, with participation from Oxford Finance and BroadOak Capital Partners. Proceeds of the financing will support the global commercial … engineering, synthesis of biological libraries for drug discovery, and CRISPR genome editing. Simply put, what used to take up to six weeks can now be performed within a few hours and with only the push …

SGI-DNA Secures $25 Million Series A Financing to Support Commercial Launch | Business & Finance | heraldchronicle.com | Business Wire | 9/9/2019

… DNA data storage solutions, has completed a $25 million Series A financing round led by Northpond Ventures, with participation from Oxford Finance and BroadOak Capital Partners. Proceeds of the financing will support the global commercial … engineering, synthesis of biological libraries for drug discovery, and CRISPR genome editing. Simply put, what used to take up to six weeks can now be performed within a few hours and with only the push …

Google Ventures

Brainstorm Health: J&J Hip Implant Payout, New Gene Editing Company, Exercise and Marijuana | Fortune | 5/8/2019

… Google Ventures) is backing an ambitious bid by a new gene editing company called Verve Therapeutics to develop groundbreaking new drugs for heart diseases. GV is giving the company, whose chief executive will be respected Broad Institute of Harvard & MIT cardiologist, a $58.5 million infusion to pursue genome editing treatments for coronary artery disease (CAD), a massive risk factor for heart attacks. ( FierceBitoech ) Advertisement INDICATIONS Johnson & Johnson to shell out …

Brainstorm Health: J&J Hip Implant Payout, New Gene Editing Company, Exercise and Marijuana | Yahoo News | 5/8/2019

… Google Ventures) is backing an ambitious bid by a new gene editing company called Verve Therapeutics to develop groundbreaking new drugs for heart diseases. GV is giving the company, whose chief executive will be respected Broad Institute of Harvard & MIT cardiologist, a $58.5 million infusion to pursue genome editing treatments for coronary artery disease (CAD), a massive risk factor for heart attacks. ( FierceBitoech ) INDICATIONS Johnson & Johnson to shell out $1 …

Fidelity Investments

CANbridge Pharmaceuticals Appoints Chief Financial Officer and Interim Chief Medical Officer | PR Newswire | 4/26/2019

Fidelity Investments. Mr. Hassan holds a Master of Science in Global Financial Analysis from McCallum Graduate School of Business, Bentley College and a Bachelor of Science in Business from Indiana University . Prior to founding his consulting practice, Dr. Cox was Chief Medical Officer for Editas Medicine, in Cambridge , where he led the clinical development of CRISPR-based genome editing medicines to treat human diseases, resulting in the first IND approval …

CANbridge Pharmaceuticals Appoints Chief Financial Officer and Interim Chief Medical Officer | PR Newswire | 4/25/2019

… Surveyor Capital) as Senior Analyst covering mid- and large-cap global therapeutics equities. Earlier in his career he worked at Fidelity Investments. Mr. Hassan holds a Master of Science in Global Financial Analysis from McCallum … Cambridge , where he led the clinical development of CRISPR-based genome editing medicines to treat human diseases. Dr. Cox also had a long stint at Sanofi Genzyme, also in Cambridge , culminating as Vice President, Rare …

Ampersand Capital Partners

Sangamo Announces Strategic Investment In Manufacturing And Appointment Of Andy Ramelmeier As Head Of Technical Operations | CNBC | 11/10/2017

… ownership of product development and to forward-integrate, on our own and with partners, to capture the value of our genome editing and gene therapy pipeline,” said Curt Herberts, chief business officer of Sangamo. “Brammer … medicines to improve patient health. Brammer Bio is owned by Ampersand Capital Partners, the only institutional investor in the company, and its founders. For more information, please visit www.brammerbio.com . For inquiries or more information on …

Sangamo Announces Strategic Investment In Manufacturing And Appointment Of Andy Ramelmeier As Head Of Technical Operations | PR Newswire | 11/9/2017

… ownership of product development and to forward-integrate, on our own and with partners, to capture the value of our genome editing and gene therapy pipeline,” said Curt Herberts, chief business officer of Sangamo. “ Brammer … medicines to improve patient health. Brammer Bio is owned by Ampersand Capital Partners, the only institutional investor in the company, and its founders. For more information, please visit www.brammerbio.com . For inquiries or more information on …

Leerink Partners

Intellia Therapeutics Announces Pricing Of Public Offering Of Common Stock - TheStreet | 11/2/2017

CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) – Intellia Therapeutics, Inc. (Nasdaq:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today announced the pricing of an … to be sold by Intellia. Credit Suisse, Jefferies LLC, and Leerink Partners are acting as joint book-running managers of the offering. The offering is expected to close on or about November 6, 2017, subject …

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock | CNBC | 11/2/2017

CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) – Intellia Therapeutics, Inc. (Nasdaq:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today announced the pricing of an … to be sold by Intellia. Credit Suisse, Jefferies LLC, and Leerink Partners are acting as joint book-running managers of the offering. The offering is expected to close on or about November 6, 2017, subject …

OHSU

LogicBio Therapeutics Extends Sponsored Research Agreement with Oregon Health & Science University to Explore Translation of Pharmaceutically-Driven Selective Advantage for Future GeneRide™ Candidates | Globe Newswire | 12/17/2019

CAMBRIDGE, Mass., Dec. 17, 2019 (GLOBE NEWSWIRE) – LogicBio Therapeutics, Inc. (Nasdaq: LOGC ), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced it has entered into an exclusive license with Oregon Health & Science University (“OHSU”) to intellectual property rights owned by OHSU while also extending a sponsored research agreement (“SRA”) to explore methods for enhancing selective advantage of edited hepatocytes using pharmacological …

Moffitt Cancer Center

Precision BioSciences Presents Updated Interim Clinical Data at the ASH Annual Meeting from Relapsed / Refractory NHL and B-ALL Patients Treated at Dose Levels 1 & 2 in the Ongoing Phase 1/2a Clinical Trial of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate | Globe Newswire | 12/9/2019

… event today starting at 8:15 p.m. ET, with live webcast available online- DURHAM, N.C., Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS … pharmaceutical company. Data will be presented by Bijal Shah, MD, Moffitt Cancer Center, at the 61 st Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, during a poster session from 6:00-8:00 …

UT Southwestern Medical Center

Stem Cell Technology: The Only Constant Is Change | 12/2/2019

… the development of reprogramming techniques and the generation of induced pluripotent stem cells (iPSCs). More recently, advances in biotechnology and genome editing have fostered a modern evolution of stem cell advances that shows no signs … on wound healing and aging. Jun Wu, PhD, Assistant Professor, UT Southwestern Medical Center In collaboration with Jun Wu, PhD, assistant professor at UT Southwestern Medical Center and a former postdoc in the Belmonte laboratory …

Johns Hopkins University School of Medicine

Genome Editing Services Market-Focus on CRISPR, 2019-2030 | PR Newswire | 11/28/2019

Genome Editing Services Market-Focus on CRISPR, 2019-2030 News provided by Nov 28, 2019, 08:00 ET NEW YORK , Nov. 28, 2019 /PRNewswire/ – INTRODUCTION The 1970s witnessed the introduction of one of the most revolutionary advances in biotechnology, when Hamilton Smith (a molecular biologist at Johns Hopkins University School of Medicine ) purified the first site-specific restriction enzyme , called Hind II. This development enabled the scientific community to devise the means …

University of Texas MD Anderson Cancer Center

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool | PR Newswire | 11/28/2019

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool News provided by Research and Markets Nov 28, 2019, 07:00 ET DUBLIN , Nov. 28, 2019 /PRNewswire/ – The “Genome Editing Services Market-Focus on CRISPR 2019-2030” report has been added to ResearchAndMarkets.com’s offering. This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an …

University of Rochester Medical Center, Rochester NY

Intronic SMCHD1 variants in FSHD: testing the potential for CRISPR-Cas9 genome editing | BMJ | 11/27/2019

… for Research on Cancer and Aging of Nice, Faculty of Medicine , Université Côte d’Azur , Nice , France 10 Department of Neurology , University of Rochester Medical Center , Rochester , New York , USA Correspondence to Professor Silvère M van … for extra-exonic SMCHD1 mutations. We also used CRISPR-Cas9 genome editing to repair a pathogenic intronic SMCHD1 variant from patient myoblasts. Results We identified intronic SMCHD1 variants in two FSHD families. In the first …

Leiden University Medical Center

Intronic SMCHD1 variants in FSHD: testing the potential for CRISPR-Cas9 genome editing | BMJ | 11/27/2019

Silvère M van der Maarel 1 1 Human Genetics , Leiden University Medical Center , Leiden , The Netherlands 2 Hubrecht Institute-KNAW and University Medical Center , Utrecht , The Netherlands 3 Clinical Sciences of Companion Animals , Faculty of … for extra-exonic SMCHD1 mutations. We also used CRISPR-Cas9 genome editing to repair a pathogenic intronic SMCHD1 variant from patient myoblasts. Results We identified intronic SMCHD1 variants in two FSHD families. In the first …

Medical Center

Intronic SMCHD1 variants in FSHD: testing the potential for CRISPR-Cas9 genome editing | BMJ | 11/27/2019

Silvère M van der Maarel 1 1 Human Genetics , Leiden University Medical Center , Leiden , The Netherlands 2 Hubrecht Institute-KNAW and University Medical Center , Utrecht , The Netherlands 3 Clinical Sciences of Companion Animals , Faculty of … for extra-exonic SMCHD1 mutations. We also used CRISPR-Cas9 genome editing to repair a pathogenic intronic SMCHD1 variant from patient myoblasts. Results We identified intronic SMCHD1 variants in two FSHD families. In the first …

Fred Hutchinson Cancer Research Center, Seattle WA

Intronic SMCHD1 variants in FSHD: testing the potential for CRISPR-Cas9 genome editing | BMJ | 11/27/2019

… The Netherlands 6 Center for Human and Clinical Genetics , Leiden University Medical Center , Leiden , The Netherlands 7 Division of Biology , Fred Hutchinson Cancer Research Center , Seattle , Washington , USA 8 Peripheral Nervous System, Muscle and ALS … for extra-exonic SMCHD1 mutations. We also used CRISPR-Cas9 genome editing to repair a pathogenic intronic SMCHD1 variant from patient myoblasts. Results We identified intronic SMCHD1 variants in two FSHD families. In the first …

University Medical Center

Intronic SMCHD1 variants in FSHD: testing the potential for CRISPR-Cas9 genome editing | BMJ | 11/27/2019

Silvère M van der Maarel 1 1 Human Genetics , Leiden University Medical Center , Leiden , The Netherlands 2 Hubrecht Institute-KNAW and University Medical Center , Utrecht , The Netherlands 3 Clinical Sciences of Companion Animals , Faculty of … for extra-exonic SMCHD1 mutations. We also used CRISPR-Cas9 genome editing to repair a pathogenic intronic SMCHD1 variant from patient myoblasts. Results We identified intronic SMCHD1 variants in two FSHD families. In the first …

MD Anderson Cancer Center

12 burning questions for Stephen Hahn, Trump’s pick to lead FDA | STAT | 11/20/2019

… Nicholas Florko @NicholasFlorko November 20, 2019 Dr. Stephen Hahn, President Trump’s nominee to lead the FDA The University of Texas MD Anderson Cancer Center S tephen Hahn, President Trump’s nominee to helm the Food and … cells growing in lab dishes have found that CRISPR-based genome editing can alter DNA in ways that could raise the risk of cancer and other serious diseases — but, in all likelihood, not for years …

The University of Texas MD Anderson Cancer Center

12 burning questions for Stephen Hahn, Trump’s pick to lead FDA | STAT | 11/20/2019

… to lead FDA By Nicholas Florko @NicholasFlorko November 20, 2019 Dr. Stephen Hahn, President Trump’s nominee to lead the FDA The University of Texas MD Anderson Cancer Center S tephen Hahn, President Trump’s nominee to … cells growing in lab dishes have found that CRISPR-based genome editing can alter DNA in ways that could raise the risk of cancer and other serious diseases — but, in all likelihood, not for years …

Children's Hospital

Sangamo Therapeutics Announces New Scientific Advisory Board | Business Wire | 11/8/2019

… Sangamo Therapeutics Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing, and gene regulation. For more information about Sangamo, visit www.sangamo.com . Forward-Looking Statements This press release contains forward-looking statements regarding Sangamo’s current expectations. These forward-looking statements include, without limitation, statements regarding the Company’s …

Massachusetts General Hospital

Putting one foot in front of the other | Nature | 11/8/2019

Massachusetts General Hospital (MGH). At the MGH, I utilised CRISPR-Cas9 genome editing technology to recapitulate human craniofacial anomalies in the zebrafish model organism. “I enjoy pushing my mind and body to try and exceed my limits. It’s not often that I will say no to a new challenge if I feel that I can be passionate about it and give it my 100% effort.” At Michigan, the DDS/PhD …

Memorial Sloan Kettering Cancer Center

CRISPR Approach To Fighting Cancer Called ‘Promising’ In 1st Safety Test | 11/7/2019

genome editing in patients and shows the potential of this technology to be a safe and effective therapy,” Doudna says. Dr. Michel Sadelain , who is doing related research at Memorial Sloan Kettering Cancer Center in New York, says he’s glad to see the editing of genes move into the clinic this way, though he stresses that patients will have to be followed much longer to gain confidence that the approach …

Memorial Sloan Kettering

CRISPR Approach To Fighting Cancer Called ‘Promising’ In 1st Safety Test | 11/7/2019

genome editing in patients and shows the potential of this technology to be a safe and effective therapy,” Doudna says. Dr. Michel Sadelain , who is doing related research at Memorial Sloan Kettering Cancer Center in New York, says he’s glad to see the editing of genes move into the clinic this way, though he stresses that patients will have to be followed much longer to gain confidence that the approach …

Harvard Medical School

Genome editing of HBG1 and HBG2 to induce fetal hemoglobin | Blood Advances | American Society of Hematology | 11/6/2019

GENE THERAPY November 6, 2019 Genome editing of HBG1 and HBG2 to induce fetal hemoglobin Department of Hematology, St. Jude Children’s Research Hospital, Memphis, TN; Search for other works by this author on: Division of Hematology/Oncology, Boston Children’s Hospital, Boston, MA; 3 Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; 4 Department of Pediatrics, Harvard Medical School, Boston, MA; 5 Harvard Stem Cell Institute, Cambridge, MA; 6 …

University of Rochester

Laboratory Technician IV (S) - 211587 - Rochester, NY, , USA #jobs #Rochester pls RT | 10/30/2019

Job Detail for Laboratory Technician IV (S) - 211587 Job Location: University of Rochester, Rochester, NY, , USA Job Detail for Laboratory Technician IV (S) - 211587 Job Location: University of Rochester, Rochester, NY, , USA Jobs In Laboratory … is responsible for supporting mouse model generation in the Mouse Genome Editing Resource (MGE) core facility. He or she will carry out sophisticated experiments in mouse colony management and mouse genetic manipulation. Responsibilities: Under general …

Children's Hospital of Philadelphia

ASGCT Presents Career Development Awards to Six Members | PRWeb | 10/23/2019

… of non-viral mechanisms of targeting lung epithelial cells for prenatal gene editing in a large animal model Christopher Nelson, Ph.D.—assistant professor, University of Arkansas Characterizing and overcoming the host response to genome editing therapy Kalpana Parvathaneni, MS, Ph.D.— postdoctoral researcher, Center for Cellular Immunotherapies, University of Pennsylvania Engineered CAR-T Cells to Overcome Alloimmunity in Transplant Rejection ASGCT is honored to have received such strong interest from its …

Boston Children's Hospital

CANbridge Pharmaceuticals Appoints Chief Financial Officer and Interim Chief Medical Officer | PR Newswire | 4/26/2019

… Dr. Cox was Chief Medical Officer for Editas Medicine, in Cambridge , where he led the clinical development of CRISPR-based genome editing medicines to treat human diseases, resulting in the first IND approval for in … a board-certified clinical geneticist and pediatrician who trained at Boston Children’s Hospital, where he remains on staff and continues to see patients with genetic diseases. He earned an MD and PhD in Biology from …

Children's Hospital Oakland, Oakland CA

Sangamo Therapeutics Presents Initial Safety Data from CHAMPIONS Genome Editing Study for MPS II at WORLDSymposium | PR Newswire | 2/7/2018

Sangamo Therapeutics Presents Initial Safety Data from CHAMPIONS Genome Editing Study for MPS II at WORLDSymposium News provided by 19:30 ET Share this article RICHMOND, Calif., Feb. Sangamo Therapeutics, Inc. (Nasdaq: SGMO ) today announced the … principal investigator for the CHAMPIONS study at the UCSF Benioff Children’s Hospital Oakland, where the first subjects in the study were treated. Dr. Edward Conner , Chief Medical Officer of Sangamo, also commented: “We are pleased …

Tenet Healthcare Corporation

mHealth and Telemedicine Innovation Vastly Improving Healthcare Services for Patients | PR Newswire | 11/9/2017

… include: Reliq Health Technologies Inc. (OTC: RQHTF) (TSX-V: RHT), Sangamo Therapeutics, Inc. (NASDAQ: SGMO), Editas Medicine, Inc. (NASDAQ: EDIT), Tenet Healthcare Corporation (NYSE: THC), Array BioPharma Inc. (NASDAQ: ARRY ). Reliq Health Technologies Inc. (OTCQB … Healthcare Industry developments: Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, the week reported financial results for the third quarter ended September 30, 2017 , and provided an update on recent achievements and upcoming …

Jennifer Doudna

Doudna’s team identifies new ‘hypercompact’ CRISPR enzyme | FierceBiotech | 7/17/2020

… into cells efficiently because of the package’s large size. Now, a University of California, Berkeley team led by CRISPR pioneer Jennifer Doudna has identified a “hypercompact” CRISPR enzyme, CasΦ (Cas12j), in what it says is … to the researchers. The team showed CRISPR-CasΦ can perform genome editing in both human and plant cells. In one case, a variant of CasΦ was able to edit up to 33% of human cells …

David Li

Gene-editing discovery could point the way toward a ‘holy grail’: cures for mitochondrial diseases | STAT | 7/8/2020

Cells with mitochondria, in red Courtesy Tslil Ast Mootha Laboratory B iologist David Liu was in the middle of his morning commute to the Broad Institute two summers ago when he opened the email. We … muscles and brains, and eventually take their lives. advertisement The genome editing revolution has largely passed mitochondria by. CRISPR doesn’t work: The guide RNA it uses like a bloodhound to find its target within a …

David Liu

Gene-editing discovery could point the way toward a ‘holy grail’: cures for mitochondrial diseases | STAT | 7/8/2020

Cells with mitochondria, in red Courtesy Tslil Ast Mootha Laboratory B iologist David Liu was in the middle of his morning commute to the Broad Institute two summers ago when he opened the email. We … muscles and brains, and eventually take their lives. advertisement The genome editing revolution has largely passed mitochondria by. CRISPR doesn’t work: The guide RNA it uses like a bloodhound to find its target within a …

Tom Adams

U.S. Secretary of Agriculture Sonny Perdue and Pairwise Leaders Discuss Food Solutions to Health Challenges | Business Wire | 6/16/2020

… helping create opportunities for improvement. “Now more than ever, consumers need better options for healthier food choices,” said Pairwise CEO Tom Adams. “We are grateful for the opportunity to discuss with Secretary Perdue and Commissioner … nutritious food on tables across North America. From developing novel genome editing tools to leveraging the natural genetic diversity of plants to creating robust partnerships and collaborations, Pairwise is addressing the biggest challenges facing the …

Francis Crick

Scientists Edited Human Embryos in the Lab, and It Was a Disaster | Medium | 6/16/2020

… experiment do not bode well for the prospect of gene-edited babies. Biologist Kathy Niakan and her team at the Francis Crick Institute wanted to better understand the role of a particular gene in the … Organization are contemplating international standards around the use of germline genome editing in response to the global outcry over He’s experiment. The committees are expected to release recommendations this year or in 2021. But because …

Charles Albright

Editas Medicine Presents Pre-Clinical Data Supporting the use of CRISPR-Cas12a to Edit Induced Pluripotent Stem Cells for the Development of Engineered Cell Immunotherapies | Globe Newswire | 5/15/2020

CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) – Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced results from a pre-clinical study evaluating multi-gene knockout and transgene knock-in using its … make a meaningful impact in the treatment of cancer,” said Charles Albright, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine. “We are focused on solid tumors given the high unmet need and will …

John Leonard

Intellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy | Globe Newswire | 5/12/2020

… in non-human primate study for our newest development candidate, NTLA-2002 CAMBRIDGE, Intellia Therapeutics, Inc. (NASDAQ: NTLA ), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo … with NTLA-5001 next year,” said Intellia President and CEO John Leonard, M.D. “We are also pleased to present data that support our recently announced HAE development candidate, NTLA-2002, Intellia’s second systemic therapy employing …

Udit Batra

MilliporeSigma Granted U.S. Patents for Foundational CRISPR-Cas9 Technology | PR Newswire | 5/11/2020

… other uses - Committed to ethical use of genome-editing technology BURLINGTON, Mass. , May 11, 2020 /PRNewswire/ – MilliporeSigma , a leader in genome editing, today announced that two of its CRISPR-Cas9-assisted genome-editing patents have … applications and can be used to develop personalized therapies,” said Udit Batra , CEO, MilliporeSigma. “As a leading innovator of CRISPR technology, we will license this technology to ensure that the full potential of this powerful …

Steve Nelson

Pairwise and Plant Sciences, Inc. (PSI) Partner to Bring New Varieties of Black Raspberries, Red Raspberries and Blackberries in the United States | Business Wire | 4/15/2020

… will work with Pairwise to identify and advance innovation that will benefit the berry landscape,” said PSI’s Chief Executive Officer Steve Nelson. “This partnership will afford us the opportunity to bring to consumers novel and … nutritious food on tables across North America. From developing novel genome editing tools to leveraging the natural genetic diversity of plants to creating robust partnerships and collaborations, Pairwise is addressing the biggest challenges facing the …

David Thom

Precision Biosciences Appoints Dora Alvarado as Senior Vice President of Human Resources | Globe Newswire | 4/15/2020

… BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS ® genome editing platform, today announced that Dora Alvarado has joined the leadership team as Senior … continue our growth in cell therapy and gene editing,” commented David Thomson, PhD, Chief Operating Officer of Precision BioSciences. Ms. Alvarado joins Precision BioSciences with more than 25 years of experience developing and leading high …

Bijal Shah

Precision BioSciences Presents Updated Interim Clinical Data at the ASH Annual Meeting from Relapsed / Refractory NHL and B-ALL Patients Treated at Dose Levels 1 & 2 in the Ongoing Phase 1/2a Clinical Trial of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate | Globe Newswire | 12/9/2019

… event today starting at 8:15 p.m. ET, with live webcast available online- DURHAM, N.C., Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS … Servier, an international pharmaceutical company. Data will be presented by Bijal Shah, MD, Moffitt Cancer Center, at the 61 st Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, during a poster …

He Jiankui

Tech – Metro | China’s genetic modification of humans has created mutant babies, scientists claim | 12/4/2019

Chinese scientist He Jiankui defends his work during a panel discussion at the Second International Summit on Human Genome Editing in Hong Kong (Picture: EPA) A controversial Chinese genetic experiment may have resulted in the creation of two babies with mutated genes, scientists have warned. Last year, biophysicist He Jiankui edited the DNA of twin girls called Lulu and Nana in a bid to make them immune to HIV. But …

Emmanuelle Charpentier

Harnessing the power of CRISPR in space and time | Phys Org | 12/2/2019

… discoveries for this technique in fact was laid in Vienna and published in 2012 in a study co-authored by Emmanuelle Charpentier and VBC Ph.D. student, Krzysztof Chylinski. Due to its power to also edit … sickle cell anemia was announced. To control the power of genome editing, several groups have worked on systems to control editing activity. Scientists from the lab of Ulrich Elling at IMBA were now able to …

Feng Zhang

Cyrus, the Broad team up to make in vivo CRISPR use safer | FierceBiotech | 12/2/2019

… Feng Zhang, who had a hand in developing CRISPR, will serve as the Broad’s principal investigator for the collaboration. One concern with using CRISPR-Cas9 to perform in vivo genome editing stems from the risk that the body will mount an immune response against the system. Those concerns have grown as researchers have shown that many people have antibodies against Cas9, reflecting the fact that the homologs of the protein …

Fred Hutchinson

Intronic SMCHD1 variants in FSHD: testing the potential for CRISPR-Cas9 genome editing | BMJ | 11/27/2019

… The Netherlands 6 Center for Human and Clinical Genetics , Leiden University Medical Center , Leiden , The Netherlands 7 Division of Biology , Fred Hutchinson Cancer Research Center , Seattle , Washington , USA 8 Peripheral Nervous System, Muscle and ALS … for extra-exonic SMCHD1 mutations. We also used CRISPR-Cas9 genome editing to repair a pathogenic intronic SMCHD1 variant from patient myoblasts. Results We identified intronic SMCHD1 variants in two FSHD families. In the first …

Katrine Bosley

Arrakis Therapeutics Appoints Katrine Bosley as Chairman of the Board of Directors | Business Wire | 11/21/2019

… the discovery of a new class of small-molecule medicines that directly target RNA, announced today that it has appointed Katrine Bosley as Chairman of its Board of Directors. Ms. Bosley is a proven biotechnology … VP Business Development) and developed innovative products and technologies (CRISPR genome editing, Tysabri (natalizumab), covalent drugs). Her experiences include Chairing the Emerging Companies Section of the Board of BIO; serving as the Entrepreneur-in-Residence …

Denis Rebrikov

Human germline editing needs one message | Nature | 11/20/2019

… in China whose genomes had been edited to prevent HIV infection. Undeterred by the global opprobrium heaped on He, Russia’s Denis Rebrikov told Nature last month about more experiments involving gene editing of human eggs … the blueprint of life. Read the paper: Search-and-replace genome editing without double-strand breaks or donor DNA The speed of technological advance, coupled with some scientists’ determination to press ahead with editing human …

Ned Sharpless

12 burning questions for Stephen Hahn, Trump’s pick to lead FDA | STAT | 11/20/2019

… bumped to 2022, until a federal court ordered it moved up to May 2020. Earlier this year, acting FDA Commissioner Ned Sharpless said in a congressional hearing that the agency “should have acted sooner” to … cells growing in lab dishes have found that CRISPR-based genome editing can alter DNA in ways that could raise the risk of cancer and other serious diseases — but, in all likelihood, not for years …

Sarah Cannon

2 patients with blood disorders benefit from CRISPR treatment | Becker’s Hospital Review | 11/20/2019

… For less than a year, both patients haven’t needed blood transfusions and have reduced disease symptoms, sparking the possibility that genome editing could one day offer a safe, lasting cure for both diseases. The trial … Haydar Frangoul, MD, a hematology/oncology specialist of HCA Healthcare’s Sarah Cannon Research Institute in Nashville, Tenn., told STAT. The patient suffered sepsis, gallstones and abdominal pain after treatment. After the encouraging results from the …

Samarth Kulkarni

First CRISPR treatment for blood diseases shows early benefits in two patients | STAT | 11/19/2019

… been free from blood transfusions and disease symptoms for a relatively short time, but the encouraging data offer hope that genome editing might one day offer a safe, durable cure for both blood diseases. The … but it’s impact on human health was less clear,” said Samarth Kulkarni, chief executive of CRISPR Therapeutics. “These results tell us that CRISPR-based medicines are arriving. At the same time, we recognize that there …

Adam Feuerstein

First CRISPR treatment for blood diseases shows early benefits in two patients | STAT | 11/19/2019

Biotech First CRISPR treatment for blood diseases shows early benefits in two patients By Sharon Begley @sxbegle and Adam Feuerstein @adamfeuerstein November 19, 2019 Red blood cells from a person with sickle cell disease. Jonathan … relatively short time, but the encouraging data offer hope that genome editing might one day offer a safe, durable cure for both blood diseases. The companies, CRISPR Therapeutics ( CRSP ) and Vertex ( VRTX ) Pharmaceuticals, have competition …

Adrian Woolfson

Sangamo Therapeutics Announces New Scientific Advisory Board | Business Wire | 11/8/2019

… identify new opportunities for differentiation and innovation in the genomic medicine space, and to define and address future trends,” said Adrian Woolfson, B.M., B.Ch., Ph.D., Head of Research and Development. “As Sangamo continues to advance … gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing, and gene regulation. For more information about Sangamo, visit www.sangamo.com . Forward-Looking Statements This press release contains forward-looking statements regarding Sangamo’s current …

Dwayne Dundore

$YGYI Granted Registered Hemp Seed Dealer License in the State of Florida | 11/8/2019

… housed with dehumidification systems and will be located on our 45-acre tract of land in Central Florida,” said Dr. Dwayne Dundore, President of Khrysos. “We are proud to be granted this Seed Dealer License … this division of our company. We believe his expertise in genome editing, tissue culture production, clonal propagation, and seed production provides us with an opportunity to take a leading role in the Hemp Industry.” About …

Sandy Macrae

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/7/2019

… 2019 Earnings Conference Call November 6, 2019 5:00 PM ET Company Participants McDavid Stilwell - Vice President-Corporate Communications & Investor Relations Sandy Macrae - Chief Executive Officer Adrian Woolfson - Head of Research & Development Bettina Cockroft - Chief Medical … gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing and in vivo gene regulation. As we move ahead with a robust pipeline of genomic medicines across these various platforms, we understand that …

Ritu Baral

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/7/2019

… Corporate Strategy Sung Lee - Chief Financial Officer Conference Call Participants Maury Raycroft - Jefferies Gena Wang - Barclays Whitney Ijem - Guggenheim Securities Ritu Baral - Cowen Eric Joseph - JPMorgan Yanan Zhu - Wells Fargo Securities Operator Good afternoon, and … gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing and in vivo gene regulation. As we move ahead with a robust pipeline of genomic medicines across these various platforms, we understand that …

State of North Carolina

Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR269A for Multiple Myeloma | Globe Newswire | 6/8/2020

… Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS ® genome editing platform, today announced that the first patient has been dosed in a Phase … in-house Manufacturing Center for Advanced Therapeutics (MCAT) in Durham, North Carolina. PBCAR269A has received Orphan Drug Designation from the FDA for the treatment of multiple myeloma. About the PBCAR269A Clinical Trial PBCAR269A is being …

State of California

Doudna’s team identifies new ‘hypercompact’ CRISPR enzyme | FierceBiotech | 7/17/2020

… thing, it’s difficult to deliver the material into cells efficiently because of the package’s large size. Now, a University of California, Berkeley team led by CRISPR pioneer Jennifer Doudna has identified a “hypercompact” CRISPR enzyme … to the researchers. The team showed CRISPR-CasΦ can perform genome editing in both human and plant cells. In one case, a variant of CasΦ was able to edit up to 33% of human cells …

Durham, North Carolina

Recent Investment Analysts’ Ratings Updates for Precision BioSciences (DTIL) | 6/19/2020

genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina. “ 6/1/2020 – Precision BioSciences was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $7.75 price target on the stock. According to Zacks, “Precision BioSciences, Inc …

New York, New York

Creative Biogene Releases Genome Editing Services to Support The New Era in Molecular Biology | 6/25/2020

Microbiosci announced that it has released microbial genome editing services which will backup the new ear in molecular biology research and further development. New York, USA - June 25, 2020 /MarketersMedia/ — Microbiosci, the division of Creative Biogene, the leading biotechnology solutions company with a unique blend of life sciences domain expertise and state-of-the-art technology capabilities that will complement and help accelerate the research in pharmaceutical and biotechnology industry …

York, Pennsylvania

Creative Biogene Releases Genome Editing Services to Support The New Era in Molecular Biology | 6/25/2020

Microbiosci announced that it has released microbial genome editing services which will backup the new ear in molecular biology research and further development. New York, USA - June 25, 2020 /MarketersMedia/ — Microbiosci, the division of Creative Biogene, the leading biotechnology solutions company with a unique blend of life sciences domain expertise and state-of-the-art technology capabilities that will complement and help accelerate the research in pharmaceutical and biotechnology industry …

State of New York

Creative Biogene Releases Genome Editing Services to Support The New Era in Molecular Biology | 6/25/2020

Microbiosci announced that it has released microbial genome editing services which will backup the new ear in molecular biology research and further development. New York, USA - June 25, 2020 /MarketersMedia/ — Microbiosci, the division of Creative Biogene, the leading biotechnology solutions company with a unique blend of life sciences domain expertise and state-of-the-art technology capabilities that will complement and help accelerate the research in pharmaceutical and biotechnology industry …

State of Massachusetts

LogicBio Therapeutics (NASDAQ:LOGC) Upgraded at Zacks Investment Research - Transcript Daily | 6/29/2020

genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The company’s technology platform consists of GeneRide(TM). LogicBio Therapeutics Inc. is based in Cambridge, Massachusetts. “ Get LogicBio Therapeutics alerts: Several other research analysts also recently weighed in on LOGC. Chardan Capital restated a buy rating and issued a $20.00 target price on shares of LogicBio Therapeutics in a research note …

Cambridge, Massachusetts

LogicBio Therapeutics (NASDAQ:LOGC) Upgraded at Zacks Investment Research - Transcript Daily | 6/29/2020

genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The company’s technology platform consists of GeneRide(TM). LogicBio Therapeutics Inc. is based in Cambridge, Massachusetts. “ Get LogicBio Therapeutics alerts: Several other research analysts also recently weighed in on LOGC. Chardan Capital restated a buy rating and issued a $20.00 target price on shares of LogicBio Therapeutics in a research note …

Chapel Hill, North Carolina

Multiple mechanisms regulate H3 acetylation of enhancers in response to thyroid hormone | 5/27/2020

… PLoS Genet 16(5): e1008770. https://doi.org/10.1371/journal.pgen.1008770 Editor: Gregory P. Copenhaver, The University of North Carolina at Chapel Hill, UNITED STATES Received: October 24, 2019; Accepted: April 8, 2020; Published: May 26 … fraction of T3-regulated enhancers lacking TRBS. Using CRISPR-mediated genome editing it has previously been shown that deletion of a specific enhancer can lead to reduced H3K27Ac of interacting enhancers [ 63 ], suggesting possible functional …

Los Angeles, California

Nonviral Genetic Engineering of CAR T Cells | 6/25/2020

… of California, San Francisco, who has been pursuing the use of ribonucleoprotein (RNP) electroporation 2 and nonviral DNA templates for genome editing 3 in immune cells. “A drawback of virus is that its production is … Chen, PhD, an associate professor at the University of California, Los Angeles, and a member researcher of the Parker Institute for Cancer Immunotherapy. Consequently, the high manufacturing costs and safety concerns of viral vectors have …

Boston, Massachusetts

Research Roundup: June 5, 2020 | 6/5/2020

Boston Children’s Hospital) describes how they used base editing to restore partial hearing to mice with TMC1-related deafness — the first example of genome editing in vivo to fix a recessive sensory loss disorder. Treated mice experienced partially restored hearing and responded to loud sounds. Read more in news releases from Harvard University and Boston Children’s Hospital , and coverage in Genetic Engineering & Biotechnology News . Sperm in the spotlight Meiosis generates …

State of Minnesota

Precision genome editing enters the modern era | Phys Org | 6/15/2020

CRISPR has sparked a renaissance in genome editing. Now, next-generation CRISPR technologies let scientists modify the genome more efficiently and precisely than before. Such tools could one day serve as therapeutics, but many challenges … says Reuben Harris, an HHMI Investigator at the University of Minnesota, who helped organize the January conference. “It triggered a landslide in this area.” Today, scientists have published more than 300 papers on the technique …

State of Colorado

JPMorgan Chase & Co. Buys 146,180 Shares of Precision BioSciences Inc (NASDAQ:DTIL) - Ticker Report | 6/24/2020

… quarter. Capital World Investors now owns 4,062,000 shares of the company’s stock worth $56,421,000 after purchasing an additional 3,437,000 ArrowMark Colorado Holdings LLC raised its holdings in shares of Precision BioSciences by 71.7% in the … Precision BioSciences Company Profile Precision BioSciences, Inc operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome …